Achillion Pharmaceuticals, Inc. ACHN announced that it has started a phase I study on its first orally administered small molecule complement factor D inhibitor, ACH-4471. The randomized, ...
Complement activation is common in patients with systemic lupus erythematosus (SLE), resulting in hypocomplementemia and deposition of complement at sites of tissue damage. The availability of mice ...
The mammalian immune system is a remarkable complex of biochemical processes enabling efficient detection and prosecution of pathogens that threaten host viability. The incredible complexity of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback